Findings

What do systematic reviews say?

147 questions · 147 findings · 11 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 60 · 40.8%GRADE not reported 4 · 2.7%Very low 35 · 23.8%Low 40 · 27.2%Moderate 6 · 4.1%High 2 · 1.4%

Advance care planning vs usual care

Comfort in dying ‐ not measured · advanced dementia

The review found no eligible studies for this question.

1 finding from 1 review

Palliative care interventions in advanced dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Advance care planning vs usual care

Symptom management · advanced dementia

1 finding from 1 review

Palliative care interventions in advanced dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Very low

Medically assisted hydration vs usual care

Quality of life · adults aged 18 years and older receiving palliative care

The review found no eligible studies for this question.

1 finding from 1 review

Medically assisted hydration for adults receiving palliative care 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Medically assisted hydration vs usual care

Survival Cox regression model Study enrolment to last date of · adults aged 18 years and older receiving palliative care

1 finding from 1 review

Medically assisted hydration for adults receiving palliative care 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 200 participants
Very low

Medically assisted hydration vs usual care

Adverse events Participant events · adults aged 18 years and older receiving palliative care

1 finding from 1 review

Medically assisted hydration for adults receiving palliative care 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 242 participants
Very low

Organisation and delivery vs usual care

Advance care planning discussion occurred · advanced dementia

It is very uncertain whether organisation and delivery changes advance care planning discussion occurred compared with usual care (very low certainty).

1 finding from 1 review

Palliative care interventions in advanced dementia 2021 · Cochrane Headline outcomes only
RR 1.08 [1, 1.18]
1 study · 193 participants
Very low

Organisation and delivery vs usual care

Concordance with goals of care ‐ not measured · advanced dementia

The review found no eligible studies for this question.

1 finding from 1 review

Palliative care interventions in advanced dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

Overall survival · palliative participants with esophageal and GE‐junction carcinoma

Summary of findings table (subcomparison 1): chemotherapy or… leads to lower overall survival compared with BSC (high certainty).

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
HR 0.81 [0.71, 0.92]
5 studies · 750 participants
High

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

Progression‐free survival · palliative participants with esophageal and GE‐junction carcinoma

It is very uncertain whether summary of findings table (subcomparison 1): chemotherapy or… changes progression‐free survival compared with BSC (very low certainty).

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
HR 0.58 [0.28, 1.18]
2 studies · 540 participants
Very low

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

Toxicity · palliative participants with esophageal and GE‐junction carcinoma

It is very uncertain whether summary of findings table (subcomparison 1): chemotherapy or… changes toxicity compared with BSC (very low certainty).

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 972 participants
Very low

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

Quality of life · palliative participants with esophageal and GE‐junction carcinoma

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1129 participants
Very low

Medically assisted hydration vs placebo

QoL · adults aged 18 years and older receiving palliative care

1 finding from 1 review

Medically assisted hydration for adults receiving palliative care 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 93 participants
Very low

Medically assisted hydration vs placebo

Survival Log‐rank analysis Study enrolment to last date of · adults aged 18 years and older receiving palliative care

1 finding from 1 review

Medically assisted hydration for adults receiving palliative care 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 93 participants
Very low

Medically assisted hydration vs placebo

Adverse events NRS (scale from 0 to 10; lower score = less toxicity) · adults aged 18 years and older receiving palliative care

1 finding from 1 review

Medically assisted hydration for adults receiving palliative care 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Very low

Naldemedine vs placebo

Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low dose naldemedine vs higher dose

Symptoms of opioid withdrawal in the medium term · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

Low dose naldemedine showed no clear difference in symptoms of opioid withdrawalfin the medium termb compared with higher doses (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 112 participants
Low

Low dose naldemedine vs higher dose

Serious adverse eventsg · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 0.25 [0.03, 2.17]
1 study · 112 participants
Low

Low dose naldemedine vs higher dose

Adverse events · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction

Low dose naldemedine showed no clear difference in adverse events compared with higher doses (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 0.84 [0.67, 1.06]
1 study · 112 participants
Low

Naloxone vs placebo

Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Naloxone vs placebo

Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found